Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission

Clinical symptoms vary in thyrotoxicosis, and severity of these depends on many factors. Over the last years, impact of genetic factors upon the development and clinical significance of thyrotoxic symptoms became evident. It is known that a production of T3 in various tissues is limited by deiodinas...

Full description

Saved in:
Bibliographic Details
Main Authors: Babenko Alina, Popkova Daria, Freylihman Olga, Solncev Vladislav, Kostareva Anna, Grineva Elena
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Clinical and Developmental Immunology
Online Access:http://dx.doi.org/10.1155/2012/340542
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832548720445489152
author Babenko Alina
Popkova Daria
Freylihman Olga
Solncev Vladislav
Kostareva Anna
Grineva Elena
author_facet Babenko Alina
Popkova Daria
Freylihman Olga
Solncev Vladislav
Kostareva Anna
Grineva Elena
author_sort Babenko Alina
collection DOAJ
description Clinical symptoms vary in thyrotoxicosis, and severity of these depends on many factors. Over the last years, impact of genetic factors upon the development and clinical significance of thyrotoxic symptoms became evident. It is known that a production of T3 in various tissues is limited by deiodinase 2 (D2). Recent studies revealed that certain single nucleotide polymorphisms (including threonine (Thr) to alanine (Ala) replacement in D2 gene codon 92, D2 Thr92Ala) affect T3 levels in tissues and in serum. Individuals with Ala92Ala genotype have lower D2 activity in tissues, compared with that in individuals with other genotypes. In our study, we have assessed an association of D2 Thr92Ala polymorphism with (1) frequency of disease development, (2) severity of clinical symptoms of thyrotoxicosis, and (3) rate of remissions, in Graves' disease patients.
format Article
id doaj-art-fb8af667bdf142b18438ec99a9283008
institution Kabale University
issn 1740-2522
1740-2530
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series Clinical and Developmental Immunology
spelling doaj-art-fb8af667bdf142b18438ec99a92830082025-02-03T06:13:25ZengWileyClinical and Developmental Immunology1740-25221740-25302012-01-01201210.1155/2012/340542340542Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of RemissionBabenko Alina0Popkova Daria1Freylihman Olga2Solncev Vladislav3Kostareva Anna4Grineva Elena5Institute of Endocrinology, Almazov Federal Heart, Blood and Endocrinology Centre, 2 Akkuratova Street, Saint-Petersburg 197541, RussiaInstitute of Endocrinology, Almazov Federal Heart, Blood and Endocrinology Centre, 2 Akkuratova Street, Saint-Petersburg 197541, RussiaInstitute of Molecular Biology and Genetics, Almazov Federal Heart, Blood and Endocrinology Centre, 2 Akkuratova Street, Saint-Petersburg 197541, RussiaDepartment of Mathematical Modeling, Almazov Federal Heart, Blood and Endocrinology Centre, 2 Akkuratova street, Saint-Petersburg 197541, RussiaInstitute of Molecular Biology and Genetics, Almazov Federal Heart, Blood and Endocrinology Centre, 2 Akkuratova Street, Saint-Petersburg 197541, RussiaInstitute of Endocrinology, Almazov Federal Heart, Blood and Endocrinology Centre, 2 Akkuratova Street, Saint-Petersburg 197541, RussiaClinical symptoms vary in thyrotoxicosis, and severity of these depends on many factors. Over the last years, impact of genetic factors upon the development and clinical significance of thyrotoxic symptoms became evident. It is known that a production of T3 in various tissues is limited by deiodinase 2 (D2). Recent studies revealed that certain single nucleotide polymorphisms (including threonine (Thr) to alanine (Ala) replacement in D2 gene codon 92, D2 Thr92Ala) affect T3 levels in tissues and in serum. Individuals with Ala92Ala genotype have lower D2 activity in tissues, compared with that in individuals with other genotypes. In our study, we have assessed an association of D2 Thr92Ala polymorphism with (1) frequency of disease development, (2) severity of clinical symptoms of thyrotoxicosis, and (3) rate of remissions, in Graves' disease patients.http://dx.doi.org/10.1155/2012/340542
spellingShingle Babenko Alina
Popkova Daria
Freylihman Olga
Solncev Vladislav
Kostareva Anna
Grineva Elena
Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission
Clinical and Developmental Immunology
title Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission
title_full Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission
title_fullStr Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission
title_full_unstemmed Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission
title_short Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission
title_sort thr92ala polymorphism of human type 2 deiodinase gene hd2 affects the development of graves disease treatment efficiency and rate of remission
url http://dx.doi.org/10.1155/2012/340542
work_keys_str_mv AT babenkoalina thr92alapolymorphismofhumantype2deiodinasegenehd2affectsthedevelopmentofgravesdiseasetreatmentefficiencyandrateofremission
AT popkovadaria thr92alapolymorphismofhumantype2deiodinasegenehd2affectsthedevelopmentofgravesdiseasetreatmentefficiencyandrateofremission
AT freylihmanolga thr92alapolymorphismofhumantype2deiodinasegenehd2affectsthedevelopmentofgravesdiseasetreatmentefficiencyandrateofremission
AT solncevvladislav thr92alapolymorphismofhumantype2deiodinasegenehd2affectsthedevelopmentofgravesdiseasetreatmentefficiencyandrateofremission
AT kostarevaanna thr92alapolymorphismofhumantype2deiodinasegenehd2affectsthedevelopmentofgravesdiseasetreatmentefficiencyandrateofremission
AT grinevaelena thr92alapolymorphismofhumantype2deiodinasegenehd2affectsthedevelopmentofgravesdiseasetreatmentefficiencyandrateofremission